and the polychlorinated biphenyls (PCBs), [47] which have been linked to a number of adverse health outcomes, including cancer
This dual action-glycemic control and cardiovascular risk reduction-positions empagliflozin as a significant player in the diabetes therapeutic landscape, offering a multifaceted approach to managing a complex and multifactorial disease
3 Have your patients scan the QR code and follow the easy steps to get them started
For instance, a patient with established heart disease might particularly benefit from liraglutide or semaglutide given their cardiovascular outcome datancbi.nlm.nih.gov, whereas a patient with severe obesity might be a candidate for high-dose semaglutide or tirzepatide to achieve maximum weight loss
BucakMNTuncerPBSarizkanSBapinarNTapinarMCoyanKet al
Each of these combinations has specific considerations regarding dosing, timing, and potential interactions